* If you want to update the article please login/register
Patients with Glut1 DS who are critically ill are expected to receive triheptanoin for the treatment of critically ill patients with Glut1 DS. Patients on this intermediate-size treatment program may continue to receive triheptanoin until commercial availability of triheptanoin falls, if the drug receives regulatory approval for the specific disease indication. Fatty Acid Oxidation Disorders and Non-FAOD conditions: Available outside of the United States by individual named patient compassionate access requests.
Source link: https://clinicaltrials.gov/ct2/show/NCT03773770
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions